Updates to the Australian Pharmaceutical Benefits Scheme
22 May 2023
Update
Services Australia has published a release detailing new and amended listings of medications on the Australian Pharmaceutical Benefits Scheme (PBS), effective from 1 May 2023.
Amendments have been made to a range of medications on the PBS, including the following medications:
- Methylphenidate (Ritalin® LA) being amended to allow access for adults with a retrospective diagnosis of ADHD. This includes access to capsules containing methylphenidate hydrochloride 10 mg, 20 mg, 30 mg, 40 mg, 60mg (modified release).
- Naltrexone (Naltrexone GH®) having a reduction in authority level for the treatment of alcohol dependence.
Enquiries regarding new and amended listings can be directed to the PBS at pbs@health.gov.au.
More news & views
23 April 2026
The RANZCP Foundation 2025 Impact Report is now available
Over the past year, the Foundation has continued to build its capacity to support research and leade...
22 April 2026
The RANZCP 2025 Annual Review and 2025 Financial Review are now available
We are pleased to share with you the RANZCP 2025 Annual Review and 2025 Financial Review.
22 April 2026
2026 RANZCP Independent Director appointment
We are seeking an Independent Director who brings strong governance capability, an independent persp...